---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-045205"
form_type: "8-K"
ticker: "BFRI"
cik: "0001858685"
company_name: "Biofrontera Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T01:07:54.033824+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biofrontera Q3 revenue $9.0M (+1.5% YoY); net loss narrows; FDA approves higher Ameluz dosage

## Summary
- Total Q3 2024 revenue $9.0M, up 1.5% YoY (would have been +19% without Hurricane Milton delays of ~$1.5M).
- Net loss narrowed to $5.7M from $6.3M YoY; adjusted EBITDA -$4.6M vs -$3.9M.
- FDA approved sNDA on Oct 4 to increase max Ameluz dosage from one to three tubes per treatment.
- Phase 3 sBCC study met all endpoints: 75.9% histological clearance vs 19% placebo (p<0.0001); FDA filing expected H1 2025.
- Cash and equivalents $2.9M at Sep 30, up from $1.3M at Dec 31, 2023.

## SEC filing metadata
- accession: 0001493152-24-045205
- form_type: 8-K
- ticker: BFRI
- cik: 0001858685
- company_name: Biofrontera Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858685/000149315224045205/0001493152-24-045205-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858685/000149315224045205/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-045205
- JSON: https://secwatch.observer/filing/0001493152-24-045205.json
- Plain text: https://secwatch.observer/filing/0001493152-24-045205.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.